by admin | Jan 21, 2018 | News & Opinions, Science
Longeveron is currently enrolling subjects in its Phase 2b multi-center clinical trial designed to test the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) for the treatment of subjects with clinically diagnosed with Aging Frailty. This is the only...
by admin | Jan 21, 2018 | News & Opinions, Science
Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients with Alzheimer’s Disease. Longeveron’s Phase I, prospective, randomized, placebo-controlled, double-blinded study is designed to test the safety and efficacy of Longeveron Mesenchymal Stem...
by admin | Jan 21, 2018 | News & Opinions, Science
America is facing one of the worst influenza seasons in recent history. The influenza virus is one of the top ten causes of death in elderly people. Longeveron is conducting a multi-center, randomized, placebo controlled trial using its Longeveron Mesenchymal Stem...
by admin | Jan 21, 2018 | News & Opinions
PRESS RELEASE Marketwired Jan. 21, 2018, 08:20 AM FREEHOLD, NJ (Marketwired – January 21, 2018) – Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that President and Chief Executive Officer David Jin, M.D.,...
by admin | Jan 19, 2018 | News & Opinions
The Mayo Clinic Center for Regenerative Medicine is a co-organizer of the 2018 World Stem Cell Summit. More than 1,000 attendees are expected at the 13th annual event Jan. 22-26 in Miami, Florida. Researchers and clinical experts from Mayo Clinic will participate in...
